Publications by authors named "Zhijun Dang"
Front Immunol
October 2024
Article Synopsis
- The study aims to compare the effectiveness of transarterial chemoembolization (TACE) combined with lenvatinib and tislelizumab (TLT) versus TACE combined with lenvatinib (TL) for treating unresectable hepatocellular carcinoma.
- A total of 169 patients participated, with those receiving TLT showing superior overall survival (26 months) and progression-free survival (14 months) compared to the TL group (20 months and 9 months, respectively).
- Results indicated that specific patient groups, particularly those with larger tumors and certain health markers, benefited significantly from the TLT treatment over TL.
